Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Squamous Cell 2

Interventions

Cisplatin 8Radiotherapy 5Paclitaxel 5Docetaxel 5Cetuximab 4Carboplatin 4pembrolizumab 3figitumumab 2cemiplimab 2advexin 2Radiation 2Methotrexate 2Fluorouracil 2Drug Therapy 2Bleomycin 2vandetanib 1talimogene laherparepvec 1sintilimab 1nedaplatin 1nanocis 1methyl 5-aminolevulinate 1ficlatuzumab 1dusquetide 1brigatinib 1avasopasem manganese 1alpha-2'-deoxythioguanosine 1Vinorelbine 1Tretinoin 1Tirapazamine 1Technetium-99 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Squamous Cell × advexin × Clear all
NCT00041613 2008-04-01

Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate

Introgen Therapeutics

Phase 3 Unknown
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT00041626 2007-09-11

Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone

Introgen Therapeutics

Phase 3 Unknown
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡